最近在内分泌治疗中加入细胞周期蛋白依赖性激酶4(CDK4)和CDK6抑制剂,显著改善了激素受体阳性(HR+)患者的预后。人表皮生长因子受体2阴性(HER2-)晚期乳腺癌(ABC)。Ribociclib在大多数亚组中都有效,无论转移的数量和部位。高达10%的ABC患者,报告了寡转移状况,最近定义为具有有限数量和大小的转移性病灶的缓慢体积转移性疾病(最多5个,不一定在同一器官中),可能适合当地治疗,旨在达到完全缓解的状态。尽管在HR+中广泛使用CDK4/6抑制剂,HER2-,ABC治疗,关于本地先进的数据,无法手术的疾病和寡转移条件仍然很差。我们报道了HR+的回顾和病例系列,HER2-,接受瑞博西尼一线治疗的ABC患者,对于局部先进的寡转移条件,报告令人印象深刻的反应和良好的安全性。
The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) advanced breast cancer (ABC). Ribociclib showed to be effective across most subgroups, regardless of the number and the site of metastasis. Up to 10% of patients with ABC, reported an
oligometastatic condition, recently defined as a slow-volume metastatic disease with limited number and size of metastatic lesions (up to 5 and not necessarily in the same organ), potentially amenable for local treatment, aimed at achieving a complete remission status. Despite the wide use of CDK4/6 inhibitors in HR+, HER2-, ABC treatment, data regarding both locally advanced, inoperable disease and
oligometastatic conditions are still poor. We reported a review and
case series of HR+, HER2-, ABC patients treated with ribociclib as first-line therapy, for a locally advanced and
oligometastatic conditions, reporting an impressive response and good safety profile.